Keros Therapeutics
KROS
129 hedge funds and large institutions have $937M invested in Keros Therapeutics in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 33 reducing their positions, and 17 closing their positions.
53,800% more call options, than puts
Call options by funds: $2.16M | Put options by funds: $4K
52% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 33
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
5.4% more ownership
Funds ownership: 71.7% → 77.1% (+5.4%)
2% more funds holding
Funds holding: 126 → 129 (+3)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less capital invested
Capital invested by funds: $948M → $937M (-$11.2M)
Top Buyers
Top Sellers
KROS Hedge Fund Activity: Q1 2023 in Review
129 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q1 2023, worth a combined $937M — down 1.2% from $948M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KROS positions and 17 closed out — a net gain of 3 holders — while 50 added to existing stakes and 33 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $47M. The largest seller was Darwin Global Management, cutting an estimated $20.1M.
- 129 institutional investors held Keros Therapeutics (KROS) as of Q1 2023, up from 126 in Q4 2022.
- Funds reported $937M of Keros Therapeutics stock for Q1 2023, down 1.2% quarter-over-quarter.
- 20 funds opened new Keros Therapeutics positions in Q1 2023 and 17 closed out, a net change of +3 holders.
- The largest Keros Therapeutics buyer in Q1 2023 was Paradigm Biocapital Advisors, an estimated $47M added.
- The largest Keros Therapeutics seller in Q1 2023 was Darwin Global Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2023.